A Methodological Approach Using rAAV Vectors Encoding Nanobody-Based Biologics to Evaluate ARTC2.2 and P2X7
AAV vectors
P2X7 (purino) receptor
animal models
extracellular ATP (eATP)
extracellular NAD+
methodological approach
nanobodies (VHH)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
05
2021
accepted:
03
08
2021
entrez:
7
9
2021
pubmed:
8
9
2021
medline:
22
12
2021
Statut:
epublish
Résumé
On murine T cells, mono-ADP ribosyltransferase ARTC2.2 catalyzes ADP-ribosylation of various surface proteins when nicotinamide adenine dinucleotide (NAD
Identifiants
pubmed: 34489954
doi: 10.3389/fimmu.2021.704408
pmc: PMC8417108
doi:
Substances chimiques
Biological Products
0
P2rx7 protein, mouse
0
Receptors, Purinergic P2X7
0
Single-Domain Antibodies
0
ADP Ribose Transferases
EC 2.4.2.-
ARTC2.2 protein, mouse
EC 2.4.2.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
704408Informations de copyright
Copyright © 2021 Gondé, Demeules, Hardet, Scarpitta, Junge, Pinto-Espinoza, Varin, Koch-Nolte, Boyer and Adriouch.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2019 Apr 1;202(7):2153-2163
pubmed: 30777922
Sci Immunol. 2018 Dec 14;3(30):
pubmed: 30552101
Annu Rev Immunol. 2018 Apr 26;36:695-715
pubmed: 29490163
J Leukoc Biol. 2014 Mar;95(3):543-9
pubmed: 24212099
Cancer Res. 2012 Jun 15;72(12):2957-69
pubmed: 22505653
Front Immunol. 2018 Jul 09;9:1580
pubmed: 30038627
Nat Protoc. 2014 Jan;9(1):209-22
pubmed: 24385150
Immunity. 2017 Jul 18;47(1):15-31
pubmed: 28723547
Front Biosci. 2008 May 01;13:6716-29
pubmed: 18508690
Neuropharmacology. 2016 May;104:31-49
pubmed: 26686393
Front Immunol. 2019 Jun 07;10:1296
pubmed: 31231397
Eur J Immunol. 2018 Jun;48(6):1078-1081
pubmed: 29508376
Pharmacol Rev. 2014 Jul;66(3):638-75
pubmed: 24928329
Purinergic Signal. 2009 Sep;5(3):369-83
pubmed: 19404775
Elife. 2018 Aug 03;7:
pubmed: 30074479
J Biol Chem. 1996 Mar 29;271(13):7686-93
pubmed: 8631807
FASEB J. 2007 Nov;21(13):3490-8
pubmed: 17575259
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4586-91
pubmed: 16537393
Sci Transl Med. 2016 Nov 23;8(366):366ra162
pubmed: 27881823
Protein Sci. 2002 Jul;11(7):1657-70
pubmed: 12070318
Nature. 2011 Nov 30;481(7379):81-4
pubmed: 22139420
FASEB J. 2008 Mar;22(3):861-9
pubmed: 17928361
J Immunol. 2009 Mar 1;182(5):2898-908
pubmed: 19234185
J Exp Med. 2010 Nov 22;207(12):2561-8
pubmed: 20975043
Adv Exp Med Biol. 2017;1051:17-53
pubmed: 28676924
Nat Rev Immunol. 2016 Feb;16(2):79-89
pubmed: 26688350
J Immunol. 1999 Dec 1;163(11):6014-22
pubmed: 10570289
Adv Protein Chem Struct Biol. 2016;104:39-79
pubmed: 27038372
Front Pharmacol. 2020 May 12;11:627
pubmed: 32477120
Front Oncol. 2020 Sep 11;10:1699
pubmed: 33042812
Microbes Infect. 2012 Nov;14(14):1284-92
pubmed: 22634347
Methods Mol Biol. 2011;737:235-46
pubmed: 21590400
Front Pharmacol. 2018 Feb 01;9:39
pubmed: 29449813
Mol Cancer Ther. 2008 Aug;7(8):2288-97
pubmed: 18723476
Immunity. 2003 Oct;19(4):571-82
pubmed: 14563321
Med Microbiol Immunol. 2009 Aug;198(3):157-74
pubmed: 19529959
Front Immunol. 2015 May 19;6:204
pubmed: 26042119
Nat Rev Cancer. 2018 Oct;18(10):601-618
pubmed: 30006588
Annu Rev Immunol. 2019 Apr 26;37:325-347
pubmed: 30676821
Adv Exp Med Biol. 1997;419:99-107
pubmed: 9193642
Science. 2005 Dec 2;310(5753):1510-2
pubmed: 16322460
Immunity. 2014 Dec 18;41(6):886-97
pubmed: 25526304
Purinergic Signal. 2018 Mar;14(1):1-18
pubmed: 29164451
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
Nat Commun. 2021 Jan 28;12(1):653
pubmed: 33510147
Curr Opin Pharmacol. 2019 Aug;47:110-118
pubmed: 30986625
Nat Biotechnol. 1997 Jul;15(7):637-40
pubmed: 9219265
Oncogene. 2019 May;38(19):3636-3650
pubmed: 30655604
Sci Signal. 2009 Feb 10;2(57):mr1
pubmed: 19211509